ABSTRACT
Background SARS-CoV-2 infection elicits distinct clinical features in children and adults. Profiling the adaptive immune response following infection in children is essential to better understand and characterize these differences.
Methods Humoral and cell-mediated immune responses from unvaccinated pediatric and adult participants were analyzed following asymptomatic or mild non-Omicron SARS-CoV-2 infection. Levels of IgG and IgA targeting spike (S), receptor-binding domain (RBD), and nucleocapsid (N) proteins of SARS-CoV-2 were measured, while neutralizing antibody (nAb) titers were assessed against three viral strains (Wuhan, Omicron BA.1 and BA.4/BA.5). Specific T-cell memory responses were investigated by quantifying interferon-gamma (IFN-γ) secreting cells after stimulation with ancestral and variant strains of SARS-CoV-2, and seasonal human β- coronaviruses (HCoV)-OC43 and -HKU1.
Results The study comprised 28 children (3 to 17 [median=10] years old) and 28 adults (19 to 62 [median=42]). At a mean time of seven months (± 2.8 months) after SARS-CoV-2 infection, children and adults mounted comparable antibody levels against S and RBD, as well as similar neutralization capacity. However, children displayed a weaker cellular memory response to SARS- CoV-2 than adults, with a median of 88 [28-184] spot forming units per million of PBMCs in children compared to 208 [141-340] in adults (***, P < .001). In children, the level of IFN-γ secreting cells in response to SARS-CoV-2 corresponds to that of seasonal coronaviruses.
Conclusion Long-term memory T-cell responses to SARS-CoV-2 are enhanced in adults compared to children who demonstrate equivalent responses to SARS-CoV-2 and other HCoV.
HIGHLIGHTS
Children infected with SARS-CoV-2 show comparable binding and neutralizing antibody levels as adults seven months after infection.
There are notable differences in the intensity of the T-cell response following SARS-CoV- 2 infection between children and adults.
Children have more pronounced T-cell immunodominance towards the spike versus non- spike proteins compared to adults at seven months post-infection
In contrast, T-cell responses to SARS-CoV-2 are globally reduced in children compared to adults but are alike to other seasonal β-coronaviruses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the CHAMO Innovation Fund (FPOC# CHA-21-010) and PSI Foundation (Grant # 21-22). The RECOVER study was supported by grants from the Canadian Institutes of Health Research VR2172712 (CQ, HD) and the Public Health Agency of Canada 2122-HQ-000225 (CQ, HD). CQ is supported through a Tier 1 Canada Research Chair in Infection Prevention (CRC-2019-00055). HD and SN are supported by the Fonds de Recherche du Quebec - Sante through a Senior Clinical Research Scholar award (HD) and a doctoral research scholarship (SN). HD is also supported by the Coalition for Epidemic Preparedness Innovations and Canadian Institutes of Health Research (CVL - 179495). The funders had no role in the study design, data collection or analysis, manuscript preparation or the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Research Ethics Boards at the Children's Hospital of Eastern Ontario (CHEOREB#21/08X) and the Sainte-Justine University Hospital and Research Center (MP-21-2021-3035 and MP-21-2021-3046).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
